Share

Save

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

PHASE1RECRUITING

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors.

info
Simpliy with AI

Study details:

This is a Phase I, multi-center, open-label, dose-finding study of ATG-022 in patients with advanced solid tumours. The study design includes a Dose Escalation Phase which will enroll subjects with advanced/metastatic solid tumors, and a Dose Expansion Phase which will enroll select advanced/metastatic solid tumors with Claudin 18. 2-positive expression at the defined maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) to further evaluate the safety, tolerability, and efficacy of ATG-022.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
  • Aged at least 18 years as of the date of consent.
  • Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or not applicable for standard therapy(ies).
  • Dose Escalation Phase: all solid tumors.
  • Dose Expansion Phase: Claudin 18.2 positive solid tumors.
  • Subjects should be willing to receive a biopsy at screening, if no former available tumor tissue samples within 36 months prior to participating in the study are provided.
  • At least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
  • Estimated life expectancy of a minimum of 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Females should be using adequate contraceptive measures until 180 days after the end of treatment, should not be breastfeeding, and must have a negative pregnancy test prior to the start of dosing if of child-bearing potential or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening.
  • Male subjects should be willing to use effective contraception, ie condoms, for the duration of the study and 180 days after the final dose of study treatment.
  • Exclusion criteria

  • Primary central nervous system disease or central nervous system metastatic disease.
  • Prior exposure to a Claudin 18.2 targeting agent.
  • Prior therapy with any chemotherapy, immunotherapy, anticancer agents, or investigational products from a previous clinical study within 28 days of the first dose of study treatment or within a period during which the investigational product or systemic anticancer treatment has not been cleared from the body (eg, a period of 5 'half-lives'.
  • Prior vaccination within 28 days of the first dose of study therapy.
  • Prior any solid organ transplant. Autologous stem cell transplant or CAR-T cell infusion < 6 months prior to the first dose of study treatment.
  • Active infection including hepatitis B, and/or hepatitis C.
  • Known history of human immunodeficiency virus (HIV) infection.
  • Any unresolved toxicities from prior therapy greater than Grade 1 at the time of ICF signature, with the exception of alopecia.
  • Pregnant or nursing females.
  • History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-022.
  • Other primary malignancies developed within 5 years prior to the first dose of the study drug, except locally curable malignancies after radical treatment.
  • In the opinion of the investigator, subject's complications, or other conditions (psychological, familial, sociological, or geographical etc.) may affect protocol compliance or may be unsuitable for participation in the study.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2023-03-27

    Primary completion: 2026-06-30

    Study completion finish: 2026-06-30

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT05718895

    Intervention or treatment

    DRUG: ATG-022

    Conditions

    • Advanced/Metastatic Solid Tumors

    Find a site

    Closest Location:

    Cancer Research SA Pty Ltd

    Research sites nearby

    Select from list below to view details:

    • Cancer Research SA Pty Ltd

      Adelaide, Not Specified, Australia

    • Cabrini Health Limited

      Malvern, Not Specified, Australia

    • Integrated Clinical Oncology Network Pty Ltd (Icon)

      South Brisbane, Not Specified, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: ATG-022
    • Dose Escalation Phase:
    • for subjects with solid tumors,approximately 16-36 subjects will be enrolled .
    • Dose Expansion Phase:
    • The tumor types in the Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. The total number of patients in dose expansion will be up to approximately 120 patients.
    DRUG: ATG-022
    • Dose Escalation Phase:
    • A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of "3+3" design.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    DLTNumber of Participants with Dose Limiting ToxicityUp to 21 Days
    MTDMaximum Tolerated DoseUp to 21 Days
    RP2DRP2D= Recommended Phase 2 DoseUp to 21 Days

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    PFSProgression Free Survival12 months after the last subject enrolled
    ORROverall Response Rate12 months after the last subject enrolled
    DORDuration of Response12 months after the last subject enrolled

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

    Other trails to consider

    Top searched conditions